The role of dydrogesterone in habitual miscarriage

Habitual miscarriage is a fairly common complication of early pregnancy. In the opinion of most authors, the term habitual miscarriage is used to describe a loss of two or more pregnancies during the first 22 weeks of pregnancy. Issues of terminology and management continue to be relevant and debatable in medical professional communities and need further discussion. In addition to the medical sides of the issue, habitual miscarriage has a significant psychological impact on women and their partners. Regardless of the gestational age, the loss of pregnancy for most couples is similar in importance to the loss of a newborn and is associated with the loss of hope and plans that future parents connected with a baby who has not yet been born. After repeated losses, bereavement and emotional upheaval are further exacerbated irrespective of the term of abortion. Repeated pregnancy loss is a significant negative event in the life of a couple both from a medical and psychological point of view, that’s why the provision of adequate medical care is one of the objectives of a specialist managing pregnancy. This also involves the choice of effective disease management. Previously it was shown that luteal phase deficiency might be the cause of this phenomenon, and that hormonal deficiency had to be replenished. Many modern publications confirm that progesterone and its derivatives have an important immunomodulatory role in the habitual miscarriage. The article describes the role of progesterone in maintaining pregnancy and the results of studies devoted to the role of dydrogesterone. It also presents data of international studies on the treatment of women with habitual miscarriage.

1. Nybo Andersen A.M., Wohlfahrt J., Christens P., Olsen J., Melbye M. Maternal age and fetal loss: population based register linkage study. Bmj. 2000;320(7251):1708–1712. doi: 10.1136/bmj.320.7251.1708.

2. Bardos J., Hercz D., Friedenthal J., Missmer S.A., Williams Z. A national survey on public perceptions of miscarriage. Obstet Gynecol. 2015;125(6):1313–1320. doi: 10.1097/AOG.0000000000000859.

3. Tetruashvili N.K., Agadzhanova A.A. Dydrogesterone in the treatment of the threatened and habitual miscarriage. Meditsinskiy sovet = Medical Council. 2018;(13):68–72. (In Russ.) doi: 10.21518/2079-701X-2018-13-68-72.

4. Shikh E.V. Pharmacotherapy during pregnancy. M.: GEOTAR-Media; 2019. 208 p. Access mode.: https://www.rosmedlib.ru/book/ISBN9785970449783.html.

5. Serov V.N., Sukhikh G.T. Rational pharmacotherapy in obstetrics, gynecology and neonatology. Volume 2. Gynecology. 2nd ed. Moscow: Litterra; 2010, p. 557–559. (In Russ.) Available at: https://akusher-lib.ru/books/ratsionalnayafarmakoterapiya-v-akusherstve-ginekologii-i-neonatologii/

6. Jordan J., Craig K., Clifton D.K., Soules M.R. Luteal phase defect: the sensitivity and specificity of diagnostic methods in common clinical use. Fertil Steril. 1994;62(1):54–62. doi: 10.1016/s0015-0282(16)56815-0.

7. Li T.C., Spuijbroek M.D., Tuckerman E., Anstie B., Loxley M., Laird S. Endocrinological and endometrial factors in recurrent miscarriage. BJOG. 2000;107(12):1471–1479. doi: 10.1111/j.1471-0528.2000.tb11670.x.

8. Badawy S.Z., Westpfal E.M. Frequency of etiological factors and cost effectiveness of the work up for patients with history of recurrent pregnancy loss. Early Pregnancy. 2000;4(4):253–260. Available at: https://www.ncbi.nlm.nih.gov/pubmed/11742420.

9. Rizner T.L., Brozic P., Doucette C. et al. Selectivity and potency of the retroprogesterone dydrogesteronein vitro. Steroids. 2011;76(6):607–615. doi: 10.1016/j.steroids.2011.02.043.

10. Haas D.M., Ramsey P.S. Progestogen for preventing miscarriage. Cochrane Database Syst Rev. 2013;(10):CD003511. doi: 10.1002/14651858.CD003511.

11. Kumar A., Begum N., Prasad S., Aggarwal S., Sharma S. Oral dydrogesterone treatment during early pregnancy to prevent recurrent pregnancy loss and its role in modulation of cytokine production: a double-blind, randomized, parallel, placebo-controlled trial. Fert Steril. 2014;102(5):1357– 1363. doi: 10.1016/j.fertnstert.2014.07.1251.

12. Coomarasamy A., Williams H., Truchanowicz E., Seed P.T., Small R., Quenby S. et al. A Randomized Trial of Progesterone in Women with Recurrent Miscarriages. N Engl J Med. 2015;373(22):2141–2148. doi: 10.1056/NEJMoa1504927.

13. Saccone G., Schoen C., Franasiak J.M., Scott R.T.Jr., Berghella V. Supplementation with progestogens in the first trimester of pregnancy to prevent miscarriage in women with unexplained recurrent miscarriage: a systematic review and meta-analysis of randomized, controlled trials. Fertil Steril. 2017;107(2):430–438. doi: 10.1016/j.fertnstert.2016.10.031.

14. Lee H.J., Park T.C., Kim H.J., Norwitz E., Lee B. The Influence of Oral Dydrogesterone and Vaginal Progesterone on Threatened Abortion: A Systematic Review and Meta-Analysis. Biomed Res Int. 2017;2017:3616875. doi: 10.1155/2017/3616875.

15. Mirza F.G., Patki A., Pexman-Fieth C. Dydrogesterone use in early pregnancy. Gynecol Endocrinol. 2016;32(2):97–106. doi: 10.3109/09513590.2015.1121982.